[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341077-105":59,"doc-detail-341077-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-synthesis-and-validation-of-improved-c-mycmax-inhibitors","Development, synthesis and validation of improved c-Myc/Max inhibitors","","The pathophysiological foundations of various diseases are often subject to alteration through the utilization of small compounds, rendering them invaluable tools for the exploration and advancement of novel therapeutic strategies. In this study, a library of novel small compounds designed to target the c-Myc/Max complex was curated and screened in vitro across PANC1, MCF7, DU-145, and A549 cancer cell lines. A 25 μM dose identified potent anticancer candidates, with IC50 values down to 1.6 μM and up to 40-fold greater effectiveness than the reference molecule. c-Myc-i7 showed strong selectivity over healthy cells, and drug-likeness models were built, supporting further tumor-type investigations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-synthesis-and-validation-of-improved-c-mycmax-inhibitors/341077/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-synthesis-and-validation-of-improved-c-mycmax-inhibitors/341077.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What compounds were developed and what target did they aim to inhibit?","Question",{"text":112,"@type":113},"The study curated a library of novel small compounds specifically designed to target the c-Myc/Max complex and inhibit its activity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which cancer cell lines were used to test the c-Myc inhibitors?",{"text":117,"@type":113},"In vitro screening was performed across PANC1, MCF7, DU-145, and A549 cancer cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"How effective were the best c-Myc inhibitors, and what selectivity was reported?",{"text":121,"@type":113},"Potent compounds were identified with IC50 values as low as 1.6 μM, up to 40 times more effective than the reference molecule. c-Myc-i7 showed strong selectivity, with 37-fold preference for prostate cancer and 59-fold for breast cancer over healthy cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341077,1790637874,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","DOI: 10. 1111/jcmm.18272  \nOR I G I NAL ART I C L E  \nDevelopment, synthesis and validation of improved c-Myc/Max inhibitors  \nSümbül Yıldırım1,2,3 | Fatih Kocabaş1,2 | Arif Mermer4,5,6   \n1Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Turkey 2Graduate School of Natural and Applied Sciences, Yeditepe University, Istanbul, Turkey  \n3 Institute for Diabetes and Cancer, Helmholtz Diabetes Center, Helmholtz Center, Neuherberg, Germany 4Department of Biotechnology, University of Health Sciences, Istanbul, Turkey 5Experimental Medicine Application and Research Center, University of Health Sciences, Istanbul, Turkey  \n6UR22722, LABCİS, Faculty of Science and Technology, University of Limoges, Limoges, France  \nCorrespondence  \nFatih Kocabas, Department of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Turkey.  \nEmail: [fatih.kocabas@yeditepe.edu.tr](fatih.kocabas@yeditepe.edu.tr)  \nArif Mermer, Department of Biotechnology, University of Health Sciences-Turkey, Uskudar, Istanbul 34662, Turkey.  \nEmail: [arif. mermer@sbu.edu.tr](arif. mermer@sbu.edu.tr)  \nAbstract  \nThe pathophysiological foundations of various diseases are often subject to alteration through the utilization of small compounds, rendering them invaluable tools for the exploration and advancement of novel therapeutic strategies. Within the scope of this study, we meticulously curated a diverse library of novel small compounds meticulously designed to specifically target the c-Myc/Max complex. We conducted in vitro examinations of novel c-Myc inhibitors across a spectrum of cancer cell lines, including PANC1 (pancreatic adenocarcinoma), MCF7 (breast carcinoma), DU-145  \n(prostate carcinoma), and A549 (lung cancer) . The initial analysis involved a 25 μM dose, which enabled the identification of potent anticancer compounds effective against a variety of tumour types. We identified c-Myc inhibitors with remarkable potency, featuring IC50 values as low as 1.6 μM and up to 40 times more effective than the reference molecule in diminishing cancer cell viability. Notably, c-Myc-i7 exhibited exceptional selectivity, displaying 37-fold and 59-fold preference for targeting prostate and breast cancers, respectively, over healthy cells. Additionally, we constructed drug-likeness models. This study underscores the potential for in vitro investigations of various tumour types using novel c-Myc inhibitors to yield groundbreaking and efficacious anticancer compounds.  \nK E Y WO R D S  \nanti-cancer, c-Myc, Max, rhodanine, ultrasonication  \n1 | INTRODUCTION  \nCancer comprises a diverse group of diseases characterized by the uncontrolled growth and division of abnormal cells, culminating in the formation of malignant tumours. The potential for cancer to metastasize, or spread to other parts of the body, presents significant health risks. The choice of cancer treatment depends on factors such as the specific type and stage of the disease, as well as the patient's age and overall health. Common treatment modalities include chemotherapy, radiation therapy and surgical intervention.1  \nContinuous advancements in medical science led to the development of novel medications and therapies, aimed at improving patient outcomes while mitigating adverse effects.  \nWithin the realm of cancer biology, the MYC paralogs, including C-MYC, N-MYC and L-MYC, are frequently observed to be overexpressed in various cancer types. 2,3 This overexpression drives unregulated cell proliferation and abnormal cellular growth. Such dysregulation can result in tumour enlargement, invasiveness, and the potential for metastasis. Additionally, MYC paralogs contribute to the development of drug resistance in cancer cells  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Aut","cbCaivkcBnQoTY8e","https://ap.wps.com/l/cbCaivkcBnQoTY8e","pdf",6110803,17,"English","# Abstract\n# Keywords\n# 1 | Introduction\n## Cancer overview and treatment context\n## MYC paralogs in cancer biology\n## Rationale for inhibiting C-Myc\n## Small-molecule c-Myc inhibitors and examples","[{\"question\":\"What compounds were developed and what target did they aim to inhibit?\",\"answer\":\"The study curated a library of novel small compounds specifically designed to target the c-Myc/Max complex and inhibit its activity.\"},{\"question\":\"Which cancer cell lines were used to test the c-Myc inhibitors?\",\"answer\":\"In vitro screening was performed across PANC1, MCF7, DU-145, and A549 cancer cell lines.\"},{\"question\":\"How effective were the best c-Myc inhibitors, and what selectivity was reported?\",\"answer\":\"Potent compounds were identified with IC50 values as low as 1.6 μM, up to 40 times more effective than the reference molecule. c-Myc-i7 showed strong selectivity, with 37-fold preference for prostate cancer and 59-fold for breast cancer over healthy cells.\"}]","Development, synthesis and validation of improved c-Myc/Max inhibitors | PDF",1790040172,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a9ebfccbf8a48d1a11776fc51791527.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/420adc55c91b31cd45672b362f985779.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6039bb50e4a2652d16f7a6484ea2b1f.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b9cb798f935726ab33c51b0cb04ff81.webp",980,1287]